Hubei Vanz Pharm Co.,Ltd
Diamond Supplier Enterprise Certification
- Diamond
Supplier - 5th
years
Diamond Supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: 86-27-84492310
Tel: 008618986076206
Tel: +86 27 84492310
Tel: WhatsApp +8615927784577
Tel: +8618071739296
Mobile:
Tel: 86-27-84492310
Fax: 86-27-84402310
URL: http://www.vanzpharm.com/en/index.html
Province/state: Hubei
City: JIAYU
Street: FANHU INDUSTRY PARK
MaxCard:
Ms.Bella Li Ms.Chelsea GaoCAS NO.388082-78-8
cas 388082-78-8 99% Lapatinib ditosylate powder
| Product Name: | Lapatinib ditosylate |
| CAS: | 388082-78-8 |
| MF: | C41H40ClFN4O11S3 |
| MW: | 925.46 |
| EINECS: | 642-915-3 |
What is Lapatinib
Lapatinib is is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes. Binding occurs atthe ATP-binding site and thereby prevents phosphorylationand the subsequent activation of other kinase enzymes.ErbB-1 overexpression occurs in approximately27% to 30% of breast cancers, while ErbB-2 is over expressedin 20% to 25% of cases.The agent has demonstratedIC50 values of ＜0.2μM against ErbB-1 and 2 fromseveral different cancer cell lines and dissociates slowly(t1/2＝300 min) from these receptor TKs.The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.The agent is highly (99%) protein bound and eliminatedprimarily in the feces. The half-life of the agent increaseupon repeated dosing, taking 6 days to reach steady statethat gives an effective half-life of 24 hours. The most commonlyseen adverse effects of lapatinib therapy are skinrash and diarrhea. Skin rash is commonly seen with manyof the other TK inhibitors and agents that target ErbB-1.Lapatinib-induced diarrhea is usually mild to moderate.
Lapatinib function
For advanced or metastatic breast cancer that is overexpressed in combination with capecitabine and has received prior treatment including anthracyclines, paclitaxel, trastuzumab (Herceptin)